Secondary Schizophrenia (63 page)

et al.
Effect of phencyclidine in
G. Pharmacologic effects of

Woods J. H.,
et al.
Stereospecific
Organic Syndromes of Schizophrenia – Section 3

binding of H-3-labeled

effects of ketamine: evidence for a
responses. Arch Gen Psychiatry,

phencyclidine in brain

persisting impairment of source

1994.
51
(3):199–214.

membranes. Life Sci, 1982.

memory in recreational users.

78. Malhotra A. K., Pinals D. A.,
30
(25):2147–54.

Drug Alcohol Depend, 2004.

Weingartner H.,
et al.
NMDA
59. FDA Drug Bulletin: Ketamine

75
(3):301–8.

receptor function and human

abuse. FDA Drug Bulletin, 1979.

70. Carpenter W. T. The

cognition: the effects of ketamine
9
(4):24.

schizophrenia ketamine challenge

in healthy volunteers.

60. Dotson J. W., Ackerman D. L.,
study debate. Biol Psychiatry,

Neuropsychopharmacology, 1996.

West L. J. Ketamine abuse. J Drug
1999.
46
(8):1081–91.

14
(5):301–7.

Issues, 1995.
25
(4):751–7.

71. Kudoh A., Katagai H., Takazawa
79. Newcomer J. W., Farber N. B.,
61. Stafford P. (1992). Psychedelics
T. Anesthesia with ketamine,

Jevtovic-Todorovic V.,
et al.

Encyclopedia. Berkeley, California:
propofol, and fentanyl decreases

Ketamine-induced NMDA

Ronin Publishing.

the frequency of postoperative

receptor hypofunction as a model

psychosis emergence and

of memory impairment and

62. Maxwell J. C. Party drugs:

confusion in schizophrenic

psychosis. Neuropsycho-

properties, prevalence, patterns,
patients. J Clin Anesth, 2002.

pharmacology, 1999.
20
(2):
and problems. Subst Use Misuse,

14
(2):107–10.

106–18.

2005.
40
(9–10):1203–40.

72. Lahti A. C., Holcomb H. H.,

80. Krystal J. H., Perry E. B.,

63. Jansen K. L. R. A review of the
Medoff D. R.,
et al.
Ketamine
Gueorguieva R.,
et al.

nonmedical use of ketamine: use,

activates psychosis and alters

Comparative and interactive

users and consequences.

limbic blood-flow in

human psychopharmacologic

J Psychoactive Drugs, 2000.

schizophrenia. Neuroreport, 1995.

effects of ketamine and

32
(4):419–33.

6
(6):869–72.

amphetamine. Implications for

64. Weiner A. L., Vieira L., McKay C.

73. Malhotra A. K., Pinals D. A.,
glutamatergic and dopaminergic

A.,
et al.
Ketamine abusers
Adler C. M.,
et al.

model psychoses and cognitive

presenting to the emergency

Ketamine-induced exacerbation

function. Arch Gen Psychiatry,

department: a case series. J Emerg
of psychotic symptoms and

2005.
62
(9):985–95.

Med, 2000.
18
(4):447–51.

cognitive impairment in

81. Radant A. D., Bowdle T. A.,

65. Dillon P., Copeland J., Jansen K.

neuroleptic-free schizophrenics.

Cowley D. S.,
et al.
Does

Patterns of use and harms

Neuropsychopharmacology, 1997.

ketamine-mediated

associated with nonmedical

17
(3):141–50.

N-methyl-D-aspartate receptor

ketamine use. Drug Alcohol

74. Malhotra A. K., Adler C. M.,

antagonism cause schizophrenia-

Depend, 2003.
69
(1):23–8.

Kennison S. D.,
et al.
Clozapine
like oculomotor abnormalities?

66. Uhlhaas P. J., Millard I.,

blunts N-methyl-D-aspartate

Neuropsychopharmacology, 1998.

Muetzelfeldt L.,
et al.
Perceptual
antagonist-induced psychosis:

19
(5):434–44.

organization in ketamine users:

a study with ketamine.

82. Hetem L. A. B., Danion J. M.,
preliminary evidence of deficits

Biol Psychiatry, 1997.

Diemunsch P.,
et al.
Effect of a
on night of drug use but not 3

42
(8):664–8.

subanesthetic dose of ketamine on
days later. J Psychopharmacol,

75. Morgan C. J. A., Curran H. V.

memory and conscious awareness

2007.
21
(3):347–52.

Acute and chronic effects of

in healthy volunteers.

67. Curran H. V., Monaghan L. In and
ketamine upon human memory:

Psychopharmacology, 2000.

out of the K-hole: a comparison of
a review. Psychopharmacology,

152
(3):283–8.

the acute and residual effects of
2006.
188
(4):408–24.

83. Lofwall M. R., Griffiths R. R.,
ketamine in frequent and

76. Ghoneim M. M., Hinrichs J. V.,
Mintzer M. Z. Cognitive and

infrequent ketamine users.

Mewaldt S. P.,
et al.
Ketamine –
subjective acute dose effects of

Addiction, 2001.
96
(5):749–60.

behavioral effects of subanesthetic
intramuscular ketamine in

68. Curran H. V., Morgan C.

doses. J Clin Psychopharmacol,

healthy adults. Clin

Cognitive, dissociative and

1985.
5
(2):70–7.

Psychopharmacol, 2006.

psychotogenic effects of ketamine
77. Krystal J. H., Karper L. P., Seibyl
14
(4):439–49.

in recreational users on the night
J. P.,
et al.
Subanesthetic effects of
84. Honey G. D., O’Loughlin C.,

of drug use and 3 days later.

the noncompetitive Nmda

Turner D. C.,
et al.
The effects of a
Addiction, 2000.
95
(4):575–90.

antagonist, ketamine, in humans.

subpsychotic dose of ketamine on

69. Morgan C. J. A., Riccelli M.,
Psychotomimetic, perceptual,

recognition and source memory

Maitland C. H.,
et al.
Long-term
cognitive, and neuroendocrine

for agency: implications for

Chapter 10 – Psychotomimetic effects of PCP, LSD, and Ecstasy

pharmacological modelling of

word encoding and recognition in

contribution to encoding and

core symptoms of schizophrenia.

schizophrenia. Am J Psychiatry,

retrieval of episodic memory: an

Neuropsychopharmacology, 2006.

2004.
161
(6):1004–15.

fMRI study. Cereb Cortex, 2005.

31
(2):413–23.

93. Hofer A., Weiss E. M.,

15
(6):749–59.

85. Fletcher P. C., Honey G. D.

Golaszewski S. M.,
et al.
Neural
100. Honey R. A. E., Honey G. D.,
Schizophrenia, ketamine and

correlates of episodic encoding

O’Loughlin C.,
et al.
Acute
cannabis: evidence of overlapping
and recognition of words in

ketamine administration alters

memory deficits. Trends a Cogn

unmedicated patients during an

the brain responses to executive

Sci, 2006.
10
(4):167–74.

acute episode of schizophrenia: a
demands in a verbal working

86. Adler C. M., Goldberg T. E.,

functional MRI study. Am J

memory task: an fMRI study.

Malhotra A. K.,
et al.
Effects of
Psychiatry, 2003.
160
(10):1802–8.

Neuropsychopharmacology, 2004.

ketamine on thought disorder,

29
(6):1203–14.

94. Glahn D. C., Ragland J. D.,

working memory, and semantic

Abramoff A.,
et al.
Beyond
101. Fu C. H. Y., Abel K. M., Allin M.

memory in healthy volunteers.

hypofrontality: a quantitative

P. G.,
et al.
Effects of ketamine on
Biol Psychiatry, 1998.

meta-analysis of functional

prefrontal and striatal regions in
43
(11):811–16.

neuroimaging studies of working

an overt verbal fluency task: a

87. Honey R. A. E., Turner D. C.,
memory in schizophrenia. Hum

functional magnetic resonance

Honey G. D.,
et al.
Subdissociative
Brain Mapp, 2005.
25
(1):60–9.

imaging study. Psychopharma-

dose ketamine produces a deficit

cology, 2005.
183
(1):92–102.

95. Tamminga C. A., Thaker G. K.,
in manipulation but not

Buchanan R.,
et al.
Limbic system
102. Langsjo J. W., Salmi E., Kaisti K.

maintenance of the contents of

abnormalities identified in

K.,
et al.
Effects of subanesthetic
working memory.

schizophrenia using positron

ketamine on regional cerebral

Neuropsychopharmacology, 2003.

emission tomography with

glucose metabolism in humans.

28
(11):2037–44.

fluorodeoxyglucose and

Anesthesiology, 2004.

88. Krystal J. H., D’Souza D. C.,
neocortical alterations with deficit
100
(5):1065–71.

Karper L. P,,
et al.
Interactive
syndrome. Arch Gen Psychiatry,

103. Langsjo J. W., Kaisti K. K., Aalto
effects of subanesthetic ketamine
1992.
49
(7):522–30.

S.,
et al.
Effects of subanesthetic
and haloperidol in healthy

96. Jessen F., Scheef L., Germeshausen
doses of ketamine on regional

humans. Psychopharmacology,

L.,
et al.
Reduced hippocampal
cerebral blood flow, oxygen

1999.
145
(2):193–204.

activation during encoding and

consumption, and blood volume

89. Krystal J. H., Karper L. P., Bennett
recognition of words in

in humans. Anesthesiology, 2003.

A.,
et al.
Interactive effects of
schizophrenia patients. Am J

99
(3):614–23.

subanesthetic ketamine and

Psychiatry, 2003.
160
(7):1305–12.

104. Stone J. M., Erlandsson K., Arstad
subhypnotic lorazepam in

97. Vollenweider F. X., Leenders K. L.,
E.,
et al.
Ketamine displaces the
humans. Psychopharmacology,

Oye I.,
et al.
Differential
novel NMDA receptor SPET

1998.
135
(3):213–29.

psychopathology and patterns of

probe [I-123]CNS-1261 in

90. Morgan C. J. A., Mofeez A.,

cerebral glucose utilisation

humans in vivo. Nucl Med Biol,

Brandner B.,
et al.
Ketamine
produced by (S)- and

2006.
33
(2):239–43.

impairs response inhibition and is
(R)-ketamine in healthy

105. van Berckel B. N. M., Oranje B.,
positively reinforcing in healthy
volunteers using positron

van Ree J. M.,
et al.
The effects of
volunteers: a dose-response study.

emission tomography (PET). Eur

low dose ketamine on sensory

Psychopharmacology, 2004.

Neuropsychopharmacol, 1997.

gating, neuroendocrine secretion

172
(3):298–308.

7
(1):25–38.

and behavior in healthy human

91. Harborne G. C., Watson F. L.,
98. Holcomb H. H., Lahti A. C.,

subjects. Psychopharmacology,

Healy D. T.,
et al.
The effects of
Medoff D. R.,
et al.
Effects of
1998.
137
(3):271–81.

sub-anaesthetic doses of ketamine
noncompetitive NMDA receptor

106. Oranje B., Gispen-de Wied C. C.,
on memory, cognitive

blockade on anterior cingulate